Breaking News

Germany Sells 10-Year Bonds With Yield Below 1% for First Time

Takeda Forecasts 7.7% Increase in Operating Profit

Takeda Pharmaceutical Co. (4502), Asia’s largest drugmaker, forecast full-year operating profit will climb 7.7 percent as it curbs costs and boosts new product sales.

Operating profit will increase to 150 billion yen ($1.47 billion) in the 12 months ending March 2015, Osaka-based Takeda said in a statement to the stock exchange today.

Takeda has made acquisitions, hired executives from overseas, and cut costs in recent years to bolster growth as its best-selling diabetes drug Actos faced cheaper generic rivals. It hired Christophe Weber, a 20-year GlaxoSmithKline Plc (GSK) veteran, in April and plans to name him chief executive next year. Weber would be the first non-Japanese leader in Takeda’s more than 230-year history.

Shares of Takeda rose 1.8 percent to 4,637 yen at the close in Tokyo trading before the earnings announcement.

The company in October predicted “mid single-digit” annual revenue growth through 2017 and said operating profit should advance 20 percent or more a year over the same period. Takeda aims to extract 100 billion yen in annual costs by 2017, including by reductions in staff numbers.

The drugmaker forecast full-year revenue will increase 2 percent to 1.73 trillion yen.

To contact the reporter on this story: Kanoko Matsuyama in Tokyo at

To contact the editors responsible for this story: Anjali Cordeiro at Suresh Seshadri

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.